TP53 and acute myeloid leukemia: Given the favorable response rates when VEN is combined with other drugs in patients with AML who are ineligible for intensive chemotherapy, VEN is currently considered the first-line treatment, regardless of their mutational status, except for the presence of a TP53 mutation.32